Evidence map›Paper›PMID 29916988›Full record

ArticleTransplantation2018

Understanding the Correlation Between DSA, Complement Activation, and Antibody-Mediated Rejection in Heart Transplant Recipients.

Qiuheng Zhang, Michelle Hickey, Diana Drogalis-Kim, Ying Zheng, David Gjertson, Martin Cadeiras, Tam Khuu, Arnold S Baas, Eugene C Depasquale, Nancy J Halnon and 10 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
5.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Drug hypersensitivity reactions: review of the state of the science for prediction and diagnosis.Toxicological sciences : an official journal of the Society of Toxicology · 2024
    Review
  10. Article
  11. Review
  12. Impact of donor-specific anti-HLA antibody on cardiac hemodynamics and graft function 3 years after pediatric heart transplantation: First results from the CTOTC-09 multi-institutional study.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2023
    Article
  13. The evolving use of biomarkers in heart transplantation: Consensus of an expert panel.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2023
    Review
  14. Article
  15. Article
  16. The allograft injury marker CXCL9 determines prognosis of anti-HLA antibodies after lung transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 1 institution in 1 country.

Qiuheng ZhangUCLA Immunogenetics Center, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
Michelle HickeyUCLA Immunogenetics Center, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
Diana Drogalis-KimRainbow Babies and Children's Hospital in Cleveland, OH.
Ying ZhengUCLA Immunogenetics Center, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
David GjertsonUCLA Immunogenetics Center, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
Martin CadeirasDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
Tam KhuuDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
Arnold S BaasDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
Eugene C DepasqualeDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
Nancy J HalnonDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
Gregory PerensDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
Juan AlejosDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
Daniel CruzDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
Nsair AliDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
Richard SheminDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
Murray KwonDepartment of Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
Michael C FishbeinDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
Abbas ArdehaliDepartment of Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
Mario DengDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
Elaine F ReedUCLA Immunogenetics Center, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
University of California, Los Angeles · US

Funding

Systems Immunolobiology of Antibiotic-Persistent MRSA InfectionU01AI124319 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI YEAMAN, MICHAEL R · 2016 to 2020
$10.1M
Anti-MHC Effects on EndotheliumR01AI042819 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REED, ELAINE F · 1999 to 2014
$4.0M
NIAID NIH HHS R01 AI042819NIAID NIH HHS U01 AI124319
6 · The paper itself

Abstract

backgroundDonor-specific HLA antibodies (DSA) are associated with increased rates of rejection and of graft failure in cardiac transplantation. The goal of this study was to determine the association of preformed and posttransplant development of newly detected DSA (ndDSA) with antibody-mediated rejection (AMR) and characterize the clinical relevance of complement-activating DSA in heart allograft recipients.

methodsThe study included 128 adult and 48 pediatric heart transplant patients transplanted between 2010 and 2013. Routine posttransplant HLA antibody testing was performed by IgG single-antigen bead test. The C3d single-antigen bead assay was used to identify complement-activating antibodies. Rejection was diagnosed using International Society for Heart and Lung Transplantation criteria.

resultsIn this study, 22 patients were transplanted with preexisting DSA, and 43 patients developed ndDSA posttransplant. Pretransplant (P < 0.05) and posttransplant (P < 0.001) ndDSA were associated with higher incidence of AMR. Patients with C3d + DSA had significantly higher incidence of AMR compared with patients with no DSA (P < 0.001) or patients with C3d-DSA (P = 0.02). Nine (36%) of 25 patients with AMR developed transplant coronary artery disease compared with 17 (15.9%) of 107 patients without AMR (P < 0.05). Among the 47 patients who received ventricular assistant device (VAD), 7 of 9 VAD+ patients with preformed DSA experienced AMR compared with 7 of 38 VAD+ patients without preformed DSA, indicating presensitization to donor HLA significantly increased the risk of AMR (P < 0.01).

conclusionsPreformed and posttransplant ndDSA were associated with AMR. C3d + DSA correlates with complement deposition on the graft and higher risk of AMR which may permit the application of personalized immunotherapy targeting the complement pathway.

Indexed as

AdolescentAdultChildChild, PreschoolComplement ActivationComplement C3dFemaleGraft RejectionGraft SurvivalHeart-Assist DevicesHeart DiseasesHeart TransplantationHistocompatibility TestingHLA AntigensHumansIncidenceComplement C3dHLA AntigensIsoantibodies

Identifiers

PMID29916988
PMCPMC6153056
OpenAlexW2809669075

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.